Skip to Main Content

Author Details

Ananya Choudhury
University of Manchester and The Christie NHS Foundation Trust
2004
189
35
PMIDPaper TitleJournal TitlePublished Year
37604983The sex gap in bladder cancer survival - a missing link in bladder cancer care?Nat Rev Urol2024
37633499Development of Prostate Bed Delineation Consensus Guidelines for Magnetic Resonance Image-Guided Radiotherapy and Assessment of Its Effect on Interobserver Variability.Int J Radiat Oncol Biol Phys2024
36898871ADAPT and Improvise: Overcoming Bacillus Calmette-Guérin Unresponsiveness in Non-muscle-invasive Bladder Cancer.Eur Urol2023
37862240Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types.JNCI Cancer Spectr2023
37478391Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.J Clin Oncol2023
37217391Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.Eur Urol2023
37085598Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma.Br J Cancer2023
37240301Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer.Int J Mol Sci2023
37437607Genome-wide association study of treatment-related toxicity two years following radiotherapy for breast cancer.Radiother Oncol2023
37198374Prediction of prostate tumour hypoxia using pre-treatment MRI-derived radiomics: preliminary findings.Radiol Med2023
37397380Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost.Front Oncol2023
37330057Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis.Radiother Oncol2023
37225552Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.Clin Oncol (R Coll Radiol)2023
36517194Myths About Bladder Preservation in Muscle-Invasive Bladder Cancer.Semin Radiat Oncol2023
36517192Multidisciplinary Management and Radiotherapy Recommendations for Clinically and Pathologically Node-positive Bladder Cancer.Semin Radiat Oncol2023
36442608Comparing symptom reporting by prostate cancer patients and healthcare professionals in the international multicentre REQUITE study.Radiother Oncol2023
36870608First-in-human technique translation of oxygen-enhanced MRI to an MR Linac system in patients with head and neck cancer.Radiother Oncol2023
36462619Magnetic Resonance-Guided Adaptive Radiation Therapy for Prostate Cancer: The First Results from the MOMENTUM study-An International Registry for the Evidence-Based Introduction of Magnetic Resonance-Guided Adaptive Radiation Therapy.Pract Radiat Oncol2023
34667303Prostate zones and cancer: lost in transition?Nat Rev Urol2022
35616660The impact of an educational tool in cervix image registration across three imaging modalities.Br J Radiol2022
35611555Radiotherapy respiratory motion management in hepatobiliary and pancreatic malignancies: a systematic review of patient factors influencing effectiveness of motion reduction with abdominal compression.Acta Oncol2022
35730624Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature.Mol Med Rep2022
35431121Effect of Race and Ethnicity on Risk of Radiotherapy Toxicity and Implications for Radiogenomics.Clin Oncol (R Coll Radiol)2022
35850925To see or not to see: Evaluation of magnetic resonance imaging sequences for use in MR Linac-based radiotherapy treatment.J Med Imaging Radiat Sci2022
36612036Low CD8 T Cell Counts Predict Benefit from Hypoxia-Modifying Therapy in Muscle-Invasive Bladder Cancer.Cancers (Basel)2022
36439503Imaging hypoxia in endometrial cancer: How and why should it be done?Front Oncol2022
36174585Current best practice for bladder cancer: a narrative review of diagnostics and treatments.Lancet2022
35964765Palliative radiotherapy in cancers of female genital tract: Outcomes and prognostic factors.Radiother Oncol2022
36130474Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort.EBioMedicine2022
36351720Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT).BMJ Open2022
36195214The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study.Radiother Oncol2022
36387203High weekly integral dose and larger fraction size increase risk of fatigue and worsening of functional outcomes following radiotherapy for localized prostate cancer.Front Oncol2022
35017008Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.Int J Radiat Oncol Biol Phys2022
35101197In Reply to Ebert et al.Int J Radiat Oncol Biol Phys2022
35314092Translation of Prognostic and Pharmacodynamic Biomarkers from Trial to Non-trial Patients with Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel.Clin Oncol (R Coll Radiol)2022
35282933Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy.Clin Oncol (R Coll Radiol)2022
35033410Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with Intermediate- and High-risk Prostate Cancer.Clin Oncol (R Coll Radiol)2022
35337604Biomarkers in muscle invasive bladder cancer.Adv Clin Chem2022
35334417Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study).Lung Cancer2022
35079065Development and validation of a hypoxia-associated signature for lung adenocarcinoma.Sci Rep2022
34922879Evaluation of the palliative radiotherapy pathway in a single institute: Can an MR Linac improve efficiency?J Med Imaging Radiat Sci2022
34789395Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.Clin Radiol2022
33096102It's All the RAVE: Time to Give up on the "Chronic Radiation Proctitis" Misnomer.Gastroenterology2021
35707756Feasibility of a multiparametric MRI protocol for imaging biomarkers associated with neoadjuvant radiotherapy for soft tissue sarcoma.BJR Open2021
33494927Dosimetric Predictors of Radiotherapy-Induced Lymphocytopenia in Lung Cancer.J Thorac Oncol2021
33762140Hypoxia and its Modification in Bladder Cancer: Current and Future Perspectives.Clin Oncol (R Coll Radiol)2021
33846523A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer.Br J Cancer2021
33539743Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.Lancet Oncol2021
33756422Lost in application: Measuring hypoxia for radiotherapy optimisation.Eur J Cancer2021
33561506Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study.Int J Radiat Oncol Biol Phys2021
  • 1 - 50 of 189

Recommended Authors

Soumyajit Roy
Rush University Medical Center
Career Start Year 2013
Number of shared co-authors 11
Andrew Warner
Western University and London Regional Cancer Program
Career Start Year 2013
Number of shared co-authors 3
Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 13
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 21
Izak Faiena
Columbia University Medical Center
Career Start Year 2010
Number of shared co-authors 0
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 12
Emmanouil Fokas
Universityhospital Frankfurt
Career Start Year 2007
Number of shared co-authors 6
Bradley J Stish
Mayo Clinic
Career Start Year 2007
Number of shared co-authors 16
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 10
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 2006
Number of shared co-authors 14
Eyad Abu-Isa
Ascension Providence Hospital
Career Start Year 2005
Number of shared co-authors 10
Himanshu Nagar
New York-Presbyterian Hospital, Weill Cornell Medical Center
Career Start Year 2005
Number of shared co-authors 8
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Career Start Year 2004
Number of shared co-authors 28
Neil B Desai
University of Texas Southwestern Medical Center
Career Start Year 2004
Number of shared co-authors 12
Neha Vapiwala
Abramson Cancer Center, University of Pennsylvania
Career Start Year 2001
Number of shared co-authors 22
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 5
Drew Moghanaki
University of California Los Angeles
Career Start Year 2000
Number of shared co-authors 10
Chandana A Reddy
Cleveland Clinic
Career Start Year 2000
Number of shared co-authors 11
Girish S Kulkarni
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1999
Number of shared co-authors 3
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 11
Michael L Steinberg
University of California los angeles
Career Start Year 1996
Number of shared co-authors 17
Phuoc T Tran
University of Maryland School of Medicine
Career Start Year 1996
Number of shared co-authors 28
Laurence Collette
Belgium International Drug Development Institute
Career Start Year 1995
Number of shared co-authors 14
Jonathan D Tward
Huntsman Cancer Institute, University of Utah
Career Start Year 1994
Number of shared co-authors 10
William Robert Lee
Duke University School of Medicine
Career Start Year 1993
Number of shared co-authors 11
Theodore L DeWeese
Johns Hopkins University School of Medicine
Career Start Year 1991
Number of shared co-authors 20
David Joseph
Sir Charles Gairdner Hospital
Career Start Year 1990
Number of shared co-authors 12
Charles R Thomas
Oregon Health & Science University
Career Start Year 1990
Number of shared co-authors 3
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 28
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1976
Number of shared co-authors 26

Collaborators

Peter Hoskin
Mount Vernon Cancer Centre
Co-authored papers 51
Catharine M L West
University of Manchester
Co-authored papers 39
Robert G Bristow
University of Toronto
Co-authored papers 10
Lingjian Yang
Ankang University
Co-authored papers 9
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 8
Dirk De Ruysscher
Maastro Clinic
Co-authored papers 7
Vincent Khoo
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Co-authored papers 6
Barry S Rosenstein
Co-authored papers 6
Niluja Thiruthaneeswaran
The University of Sydney, Westmead Hospital
Co-authored papers 6
Arnulf Stenzl
Eberhard Karls University of Tubingen
Co-authored papers 5
Alison M Dunning
Co-authored papers 5
Becky A S Bibby
University of Manchester, Christie Hospital
Co-authored papers 5
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Co-authored papers 4
Alberto Briganti
IRCCS San Raffaele Scientific Institute
Co-authored papers 4
Darren L Roberts
The University of Manchester
Co-authored papers 4
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Co-authored papers 4
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 4
Lambertus A Kiemeney
Co-authored papers 3
James N'Dow
University of Aberdeen
Co-authored papers 3
Michel Bolla
universite Grenoble-Alpes (UGA)
Co-authored papers 3
Adrian L Harris
University of Oxford
Co-authored papers 3
Simon N Stacey
deCODE genetics/Amgen Inc.
Co-authored papers 3
Patrick Sulem
Co-authored papers 3
Unnur Thorsteinsdottir
University of Iceland
Co-authored papers 3
Daniel F Gudbjartsson
Co-authored papers 3
Baris Turkbey
National Cancer Institute, National Institutes of Health
Co-authored papers 3
Hendrik Van Poppel
University Hospitals Leuven
Co-authored papers 3
Katja K H Aben
Co-authored papers 3
Mark Frydenberg
Monash University
Co-authored papers 3
Clifton D Fuller
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Release 1.2